General (161) Partnerships (45) New Products (9) Acquisitions (7) New Technologies (5) Financials (3)
Pharma and Biotech (179) Corporate (27) Bioscience (8)
2021 (10) 2020 (42) 2019 (32) 2018 (25) 2017 (23) 2016 (28) 2015 (12) 2014 (7)
English (167) Deutsch (10) French (2)
Showing 1‐20 of 179
results per page
01 Apr 2021
Lonza finalise la cession de deux sites à NextPharma
Citation de Gordon Bates, président et responsable de la division Small Molecules, Lonza :
29 Mar 2021
Pionyr Immunotherapeutics Collaborates with Lonza to Support their Oncology Product Development
The collaboration aims to bring Pionyr’s third pipeline development candidate for a novel Myeloid Tuning™ target to clinical developmentLonza to...
12 Mar 2021
Altimmune Expands AdCOVID Manufacturing Collaboration with Lonza
Lonza to commission a dedicated suite for clinical and commercial supply of Altimmune’s COVID-19 vaccine candidate at its Houston (US)...
08 Mar 2021
PsiVac and Lonza Enter a Strategic Agreement for the Process Development and cGMP Manufacturing of Ixovex-1
The strategic agreement covers process development and cGMP manufacturing of Ixovex-1, a unique patented oncolytic virus designed to address key...
16 Feb 2021
Lonza Expands Solid Form Services for Small Molecule Drugs
Solid Form Services encompass all aspects of solid form screening and characterization of small molecule APIsOffering designed to complement Lonza...
28 Jan 2021
Lonza Announces High-Quality Cryopreserved Leukopaks for More Flexibility in Immunology and Cell Therapy Research
Lonza now offers fully customizable cryopreserved Leukopaks to biopharmaceutical researchers across the globeUsing a controlled rate freezing...
19 Jan 2021
NextPharma Set to Acquire Two Lonza Sites Specialized in Lipid Oral Dosage Forms
Agreement initiates process for future acquisition of Lonza sites in Ploermel (FR) and Edinburgh (UK) allowing NextPharma to broaden technology...
19 Jan 2021
NextPharma s’apprête à acquérir deux sites Lonza spécialisés dans les formes galéniques orales des lipides
Citation de Gordon Bates, président et responsable de la division Small Molecules, Lonza :
18 Jan 2021
Aruvant chooses Lonza to Manufacture ARU-1801, a Potentially curative Treatment for Sickle Cell Disease, for Pivotal Trial
Lonza to perform process development activities to establish a robust manufacturing process for ARU-1801, a potentially curative treatment for...
12 Jan 2021
Capricor Collaborates with Lonza for the Development of CAP-1002, its Cell Therapy Candidate for the Treatment of Duchenne Muscular Dystrophy and Other Indications
Capricor to leverage Lonza’s expertise in technology transfer and development of cellular therapies to take CAP-1002 through potential product...
23 Dec 2020
Arbor Biotechnologies and Lonza Enter into Gene Editing Technology Licensing Deal
The new agreement will provide Lonza with access to Arbor’s gene editing technologyQuote from David Cheng, CEO of Arbor:“Arbor's differentiated...
21 Dec 2020
Lonza Expands Conjugation Facility with Two Additional Manufacturing Suites
The expansion of bioconjugation capabilities will provide development and manufacturing capacity for pre-clinical to commercial supply1500m2 of...
15 Dec 2020
Aurinia and Lonza Announce Exclusive Agreement for Dedicated Voclosporin Manufacturing Capacity
State-of-the-Art monoplant will provide cost and production efficiency and will secure active pharmaceutical ingredient (API) supply security for...
10 Dec 2020
Lonza, Forbion and BioGeneration Ventures Announce Collaboration for Development and Manufacture of Biologics for Portfolio Companies
The four-year agreement provides benefits for portfolio companies  of Forbion and BioGeneration Ventures (BGV)Lonza to provide de-risking,...
10 Dec 2020
Lonza, Forbion and BioGeneration Ventures Announce Collaboration for Development and Manufacture of Biologics for Portfolio Companies
The four-year agreement provides benefits for portfolio companies  of Forbion and BioGeneration Ventures (BGV)Lonza to provide de-risking,...
07 Dec 2020
Lonza’s MODA-EM™ Paperless Solution to be implemented at the UK’s New Vaccines Manufacturing and Innovation Centre
The Vaccines Manufacturing and Innovation Centre in Oxfordshire (VMIC), UK has selected Lonza’s MODA-EM™ Solution to digitize its Microbiology...
02 Dec 2020
Lonza Announces Customer-Dedicated Suites for Commercialization of Bioconjugates
Two new bioconjugation suites to provide high throughput conjugation for the commercialization  of antibody-drug conjugates (ADCs) in Lonza’s Ibex®...
30 Nov 2020
Lonza Expands Development and Manufacturing Capabilities at Bend (OR) Site
Investment in dedicated early-phase development and cGMP manufacturing in Lonza BendThe first suite on-line by December 2020 will focus on...
19 Nov 2020
Lonza and Be The Match BioTherapies partner to expand Vein-to-Vein Cell and Gene Therapy Supply Chain Network
Be The Match BioTherapies as a preferred partner to provide consistent access to high-quality, healthy donor tissue and cell and gene therapy (CGT)...
18 Nov 2020
Lonza Expands Highly Potent Drug Product Development and Manufacturing Capabilities
Highly potent capability implemented in Lonza-Tampa (US) product development labsHighly potent capable Gerteis roller compactor installed for...
1 2 3 4 ... 9 >